- Gregor Kawaletz has been appointed as the new Chief Executive Officer and President of the Management Board of Mabion Biologics CDMO.
- Kawaletz brings over 20 years of CDMO sector experience, including leadership roles at NextPharma, Catalent, IDT Biologika, Albumedix (Sartorius), and Recipharm.
Mabion has appointed Gregor Kawaletz as its new Chief Executive Officer and President of the Management Board, strengthening leadership at the biologics CDMO. The appointment is aimed at advancing Mabion’s position as a trusted partner in contract manufacturing.
Kawaletz joins Mabion with more than two decades of experience in the CDMO industry. His previous roles include senior leadership positions at NextPharma, Catalent, IDT Biologika, Albumedix (now part of Sartorius), and Recipharm. Throughout his career, he has focused on commercial strategy, anticipating therapeutic trends such as orally delivered biologics and antibody–drug conjugates (ADCs), and establishing partnerships with global pharmaceutical and biotech companies.
The company emphasised that Kawaletz’s strategic vision and industry knowledge will be “invaluable as we continue to strengthen Mabion’s role as a trusted CDMO partner.”
